Thomas Tarter, MD
Surgical Oncology · Decatur, ILNPI 1114913225
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,454 of the $4,204 with a category attached, or 82.2%. 28 manufacturers reported payments, led by Teleflex LLC at 24.6% of the total. Reporting peaked in 2022 at $1,169 and has fallen 61.8% since, to $446 in 2025.
Across 160 payments — averaging $26.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teleflex LLC$1K
- Astellas Pharma US Inc$467
- Johnson & Johnson$464
- Sumitomo Pharma America, Inc.$355
- Myriad Genetic Laboratories, Inc.$281
- Pfizer$265
- plus $1K from 22 others
What the payments were for
- Travel & lodging$65716%
- Food & beverage$3,45482%
- Education$932%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teleflex LLC | 12 | $1,033 |
| Astellas Pharma US Inc | 16 | $467 |
| Johnson & Johnson(2 entities) | 21 | $464 |
| Sumitomo Pharma America, Inc. | 15 | $355 |
| Myriad Genetic Laboratories, Inc. | 15 | $281 |
| Pfizer | 15 | $265 |
| AbbVie | 11 | $245 |
| Merck | 11 | $190 |
| Progenics Pharmaceuticals, Inc. | 4 | $161 |
| Coloplast | 5 | $120 |
| AstraZeneca(2 entities) | 5 | $83 |
| Amgen | 4 | $80 |
| Olympus America Inc. | 3 | $72 |
| Clovis Oncology, Inc. | 5 | $68 |
| Bayer | 3 | $66 |
| Tolmar, Inc. | 2 | $48 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $28 |
| Foundation Medicine, Inc. | 1 | $21 |
| 180 Medical, Inc. | 1 | $20 |
| Endo Pharmaceuticals Inc. | 1 | $18 |
| Vertex | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Eisai Inc. | 1 | $16 |
| Laborie Medical Technologies Corp. | 1 | $15 |
| Genentech USA, Inc. | 1 | $15 |
| Urovant Sciences Inc | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,204 in reported general payments places this provider in the 65th percentile of 55 surgical oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 39 | $570,666 |
| OrgovyxRelugolix | 77 | $316,560 |
| GemtesaVibegron | 96 | $89,054 |
| MyrbetriqMirabegron | 88 | $73,854 |
| Mirabegron ErMirabegron | 27 | $18,704 |
| Silodosin | 125 | $14,168 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 468 | $10,669 |
| Tamsulosin Hcl | 574 | $10,072 |
| Finasteride | 692 | $8,285 |
| Testosterone | 27 | $6,263 |
| Trimethoprim | 57 | $3,888 |
| Solifenacin Succinate | 26 | $3,704 |
| Estradiol | 38 | $2,867 |
| Trospium Chloride | 16 | $1,263 |
| Cephalexin | 19 | $1,031 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $467 | $644,520127 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $355 | $405,614173 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 55 surgical oncology providers in Illinois.
Other surgical oncology in Decatur
- Fadi DahdalehChicago$198K
- Claudius ConradUrbana$174K
- Nora HansenChicago$41K
- Jeffrey WayneChicago$38K
- David BentremChicago$34K
- Mecker MollerChicago$25K
- Akhil ChawlaWarrenville$17K
- Shishir MaithelChicago$16K
- Ashley HardyWarrenville$16K
- Aslam EjazChicago$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.